All In MedTech

FDA Clearance Tracker · P060011-S045

RayOne Galaxy; Model RAO605G, RayOne Galaxy Toric; Model RAO615X

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Sep 24, 2026 (this decision)Source: openFDAMethods & limitations

PMA supplement

Decided

Sep 24, 2026

Approved

Time to decision

224 days

Received Feb 12, 2026. Calendar days, including time FDA spent waiting on the applicant.

Pathway

PMA supplement

Panel Track

Device class

Class III

The decision

FDA number
P060011-S045
Device name
RayOne Galaxy; Model RAO605G, RayOne Galaxy Toric; Model RAO615X
Applicant location
Hove, E. Sussex
Received
Feb 12, 2026
Decided
Sep 24, 2026
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P060011

Device type

Device class
Class III
Regulation
21 CFR 886.3600
Specialty
Ophthalmology

Every decision under product code MFK

FDA's approval statement

As written in FDA's record.

Approval for the RayOne Galaxy (RAO605G) and the RayOne Galaxy Toric (RAO615X). RayOne Galaxy (Model RAO605G) is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia, in adult patients in whom a cataractous lens has been removed.The IOL mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity to a monofocal IOL.RayOne Galaxy is intended for implantation in patients with less than 1.00 diopter of pre-existing corneal astigmatism. The RayOne injection system is used to fold and assist in inserting the IOL into the eye.RayOne Galaxy Toric (Model RAO615X) is intended for primary implantation in the capsular bag of the eye for the visual correction of aphakia, in adult patients in whom a cataractous lens has been removed.The IOL mitigates the effects of presbyopia by providing improved intermediate and near visual acuity while maintaining comparable distance visual acuity to a monofocal IOL.In addition, RayOne Galaxy Toric is intended to provide reduction of residual refractive astigmatism in patients with corneal astigmatism greater than or equal to 1.03 diopter, up to 3.07 diopter. The RayOne injection system is used to fold and assist in inserting the IOL into the eye.

Source documents

Other decisions for Rayner Intraocular Lenses , Ltd.

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.